Editing Out ALS: Why VCs Bet $35M on Single-AAV Gene Therapy

TORONTO – November 02, 2026 – For years, the biotechnology industry has attempted to intercept the devastating progression of amyotrophic lateral sclerosis (ALS) by targeting its downstream effects. Antisense oligonucleotides (ASOs) promised a revolution by degrading toxic RNA, but recent high-profile clinical failures have forced the industry to look deeper—all the way to the foundational DNA. Today, Toronto-based Specific Biologics announced the closing of an oversubscribed US$35 million Series A financing round, signaling a decisive shift toward editing the disease out at its genetic source.

Led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations, Genesys Capital, and the BDC Life Sciences Venture Fund, the capital injection is designed to push the company's lead therapeutic candidate into an adaptive Phase I/II clinical trial.

The target is C9ORF72-associated ALS, the most common genetic variant of the fatal neurodegenerative disease. But the true focal point for industry observers is the company's proprietary Dualase platform—a technology that claims to overcome the historical delivery bottlenecks that have hindered conventional CRISPR therapies in the central nervous system.

Engineering Out the Defect at the Source

The C9ORF72 mutation is essentially a catastrophic stutter in the genetic code—an expansion of repeated DNA sequences that generates toxic RNA and dipeptide repeat proteins, ultimately suffocating motor neurons.

Previous attempts to treat this specific mutation have yielded sobering lessons. Biogen's BIIB078 and Wave Life Sciences' WVE-004, both ASOs designed to reduce the faulty RNA, successfully lowered toxic protein levels in cerebrospinal fluid during clinical trials. Yet, neither demonstrated a clinical benefit for patients, leading to the discontinuation of both programs. The prevailing theory among neurobiologists is that merely bailing water out of the boat is insufficient; the hole in the hull must be repaired.

"This financing represents a defining step toward our goal of bringing a potentially transformative medicine to people living with ALS," said Brent Stead, Chief Executive Officer of Specific Biologics. "Our goal is to address the disease at its genetic source to create a new therapeutic option for patients who have waited far too long."

Specific Biologics aims to achieve this through its Dualase platform, which diverges significantly from traditional CRISPR/Cas9 systems. Instead of making a single cut or creating compatible DNA ends that can lead to unpredictable repairs, Dualase employs a unique two-site cutting mechanism. By generating non-compatible DNA ends, the system forces the cell's natural repair pathways into predictable, defined-length deletions. In preclinical models, this approach achieved a near-complete collapse of the pathogenic C9ORF72 repeat expansion without detectable off-target effects.

The Single-AAV Delivery Advantage

While the molecular elegance of a gene editor is critical, the grim reality of neuro-therapeutics is that delivery dictates destiny. The blood-brain barrier remains one of the most formidable obstacles in modern medicine, and achieving widespread distribution into deep brain tissues and spinal motor neurons is notoriously difficult.

This is where conventional gene editing has historically stumbled. Standard CRISPR/Cas9 components are physically large, often requiring multiple adeno-associated virus (AAV) vectors for delivery. Multi-vector systems not only complicate manufacturing but dramatically increase the required viral load. High-dose systemic AAV administration carries severe risks, including documented cases of fatal hepatotoxicity and thrombotic microangiopathy in other gene therapy trials.

Specific Biologics has engineered a critical structural advantage: the Dualase editor has a compact coding size of approximately 3.7 kilobases. This allows the entire therapeutic payload to fit snugly inside a single AAV vector.

"Gene editing has the potential to transform the treatment of genetic diseases, but realizing that promise requires overcoming longstanding challenges in precision, specificity and delivery," said Ben Scruggs, Partner at Hatteras Venture Partners. "Specific Biologics has developed a highly differentiated technology with significant therapeutic and commercial potential designed to address these challenges, supported by compelling preclinical evidence."

By utilizing a single AAV, the company can likely pursue direct central nervous system delivery—such as intrathecal administration into the cerebrospinal fluid. As one neurobiology researcher noted, direct CNS delivery not only requires lower overall viral doses, mitigating systemic liver toxicity, but it can also bypass pre-existing systemic immunity to AAV capsids, a barrier that frequently disqualifies patients from gene therapy trials.

Beyond Symptom Management in Adaptive Trials

The immediate hurdle for Specific Biologics is translating compelling preclinical data into human efficacy. The $35 million Series A will fund an adaptive Phase I/II clinical trial aimed at achieving initial clinical biomarker proof-of-concept in the first cohort of C9ORF72-ALS patients.

Adaptive trial designs are increasingly favored in neurodegenerative research because they allow for real-time adjustments to dosing and cohort sizes based on interim data, rather than waiting years for a rigid trial to conclude. For ALS—a disease characterized by the rapid, fatal loss of voluntary muscle movement, speech, and breathing—time is a luxury patients do not possess.

The primary focus will be on safety and biomarker validation. While clinical functional scales take time to show divergence, researchers will be looking closely at cerebrospinal fluid biomarkers. A reduction in poly(GP) dipeptide repeat proteins or a stabilization of neurofilament light chain levels would provide early validation that the Dualase editor is actively excising the DNA repeats in living human motor neurons.

"Specific Biologics has assembled a dynamic and experienced team in the field of genome editing and an excellent syndicate of investors with the strategic vision to translate breakthrough science into clinical proof of concept," said Paul Hastings, Board Chair of Specific Biologics. "Their technology has the potential to redefine what is possible in gene editing and open the door to therapeutic approaches for devastating genetic conditions that have historically been beyond reach."

Financing Deep Tech Biology

Raising an oversubscribed $35 million Series A in the current biotech funding climate is a testament to the syndicate's belief in the platform's mechanistic differentiation. However, clinical trials in the central nervous system are notorious cash incinerators. The crucial question is whether this capital provides sufficient runway to reach a definitive biomarker inflection point.

The investor syndicate brings substantial operational weight to the table. Hatteras Venture Partners has a proven track record in CNS exits, having previously backed Vigil Neuroscience through its IPO and eventual acquisition. Lumira Ventures, which recently closed a record-breaking $220 million Canadian life sciences fund, adds deep pockets for potential follow-on rounds.

"Our decision to invest meaningful additional capital in Specific reflects our growing conviction in the scientific differentiation, clinical potential and long-term value of the Dualase platform," said Nikhil Thatte, Partner at Lumira Ventures. "We believe the opportunity to generate early clinical proof-of-concept in ALS patients represents an important inflection point for the company and a meaningful step toward realizing the broader promise of its technology."

That broader promise is the true economic engine behind the Series A. Repeat expansion disorders are not limited to C9ORF72-ALS; they encompass more than 40 severe genetic conditions, including Huntington's disease and various spinocerebellar ataxias. If Specific Biologics can prove that a single-AAV Dualase editor can safely and permanently excise a repeat expansion in the human nervous system, they will not have just advanced an ALS treatment. They will have validated a highly scalable platform capable of rewriting the underlying architecture of dozens of currently incurable diseases.